
    
      Part 1 of the study is double-blind and at least 48 weeks in duration. Part 2 will commence
      once the dose is confirmed based on data through Week 48 from all participants in Part 1. In
      Parts 2 and 3, participants receive open-label treatment through Week 144.
    
  